Aleor Dermaceuticals, the wholly-owned subsidiary of Alembic Pharma, today received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%, a statement from Alembic Pharma notified.

The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD) Epiduo Forte Topical Gel, 0.3%/2.5%, of Galderma Laboratories, the statement said.

It further mentioned that Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5% is indicated for the topical treatment of acne vulgaris in adults and paediatric patients 12 years of age and older.

Other drugs approval by USFDA

USFDA gives final approval for Empagliflozin tablets

USFDA gives final approval to market this anti-inflammatory skin cream

USFDA grants approval for generic Cyclosporine Soft Gel capsules

USFDA gives nod for Diclofenac Sodium Topical Gel

USFDA gives nod for generic birth control pills

USFDA gives nod for Belimumab to treat Paediatric Patients

IPC flags safety alert against immunosuppressive drug Tacrolimus

Drug recall: Atorvastatin 40 mg tablets recalled due to this reason

Govt to Create 219 Jobs for Drug Inspectors, Senior Officials to regulate Medical Devices in India

FDA raided: Fake Cosmetic manufacturing factory busted

PCI should revise B Pharm curriculum as per NEP 2020: Expert

FDA Haryana busted a fake medicine factory

FDA Maharashtra seizes diagnostic kits being sold without license

9th edition of Indian Pharmacopoeia released: Details

Govt is set to ban Codeine-based Cough Syrups and formulations

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/08/09/usfda-gives-final-approval-for-adapalene-and-benzoyl-peroxide-topical-gel-2/